<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288754</url>
  </required_header>
  <id_info>
    <org_study_id>Tumor DNA</org_study_id>
    <nct_id>NCT02288754</nct_id>
  </id_info>
  <brief_title>Detection of Tumor DNA in Blood Samples From Cancer Patients</brief_title>
  <official_title>Detection of Tumor DNA in Blood Samples From Patients With Late Stage Cancer and &quot;Healthy Controls&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexent Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexent Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to employ genomic detection methodologies to measure the relative
      amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic
      disease that is either commencing, currently undergoing or completed cytotoxic chemotherapy
      treatment. More generally, this approach will allow us to develop a quantitative measure of
      therapy efficacy via the counting of the relative changes in tumor molecules over the course
      of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the tumor load score and patient response to therapies.</measure>
    <time_frame>5 years</time_frame>
    <description>Determination of a direct correlation between the tumor load score and patient response to therapies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of particular mutation events which underlie the basis of any established correlation with therapy response.</measure>
    <time_frame>5 years</time_frame>
    <description>To determine which particular mutation events underlie the basis of any established correlation with therapy response.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cancer</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Stage II or III curative surgery</arm_group_label>
    <description>Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II or III neoadjuvant therapy cohort</arm_group_label>
    <description>Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic disease</arm_group_label>
    <description>Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>No intervention except to collect blood for diagnostic test development</description>
    <arm_group_label>Stage II or III curative surgery</arm_group_label>
    <arm_group_label>Stage II or III neoadjuvant therapy cohort</arm_group_label>
    <arm_group_label>Metastatic disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood 2 x 10 ml of Streck FFPE tumor tissue (optional)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are (i) commencing or (ii) starting a new line of treatment for metastatic
        disease with any cytotoxic chemotherapy, targeted therapy, immunotherapy, a combination of
        any and/or radiation therapy. Patients with stage II or III solid tumors undergoing
        curative intend surgery or neoadjuvant therapy followed by surgery are also eligible,
        before surgery or initiation of neoadjuvant therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Have metastatic disease with from a solid tumor (e.g. breast, lung, colon, pancreas,
             ovary, prostate...) or stage II or III solid tumors undergoing curative surgery or
             neoadjuvant therapy followed by surgery

          -  Starting treatment or a new line of treatment

          -  Able to understand and grant informed consent

          -  Able to have their blood drawn

        Exclusion Criteria:

          -  Unable to grant informed consent or comply with all study procedures.

          -  Has a hematological malignancy, i.e. myeloma, lymphoma, MDS, leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haluk Tezcan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lexent Bio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haluk Tezcan, MD</last_name>
    <phone>530-863-7922</phone>
    <email>htezcan@lexentbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayse Z Tezcan, Ph.D.</last_name>
    <phone>53-863-7936</phone>
    <email>atezcan@lexentbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>James Sinclair, MD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Sheard, MPH</last_name>
      <phone>858-342-4439</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sharp Clinical Oncology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Wood, RN</last_name>
      <phone>858-939-5062</phone>
      <email>Cathy.Wood@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Shieh Marie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chan, MD</last_name>
      <phone>310-750-3300</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DNA in Tumors</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

